Want to see AU:PKY full AI Analyst Report?
PKY Stock Chart & Stats
AU$0.04
--
Market closed
AU$0.04
--
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.08
Previous CloseN/A
VolumeN/A
Average Volume (3M)4.37M
Market Cap
AU$41.90M
Enterprise ValueAU$30.03
Total Cash (Recent Filing)AU$3.41M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta2.21
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,351,573,000
10 Day Avg. Volume2,030,105
30 Day Avg. Volume4,373,382
Financial Highlights & Ratios
PEG Ratio-0.49
Price to Book (P/B)0.74
Price to Sales (P/S)621.50
P/FCF Ratio-28.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
AI Healthcare Technology FocusThe company operates in a structurally relevant healthcare technology segment, applying AI and machine learning to clinical research and pharmaceutical decisions. A proprietary software and services model could support scalable applications if adoption and commercialization improve over time.
Debt-Free Balance SheetZero reported debt reduces financial leverage and interest burden, while the substantial equity base provides a cushion for ongoing operations and investment. This strengthens near-term financial resilience, although it does not by itself solve the company’s profitability or cash-generation challenges.
Improving Loss And Cash-Burn TrendThe improvement in cash burn and the narrowing of absolute losses indicate some progress in financial control compared with 2024. If sustained, this trend could extend the operating runway and reduce funding pressure, even though cash generation remains negative and the business is not self-funding.
Bears Say
Persistent UnprofitabilityRecurring annual losses and an extremely negative latest net margin show that the current business model is not yet converting activity into shareholder earnings. Persistent unprofitability limits internal reinvestment capacity and leaves future expansion dependent on improved execution or additional funding.
Shrinking Revenue BaseA sharply reduced revenue base weakens operating leverage and makes results more volatile because fixed costs are spread across limited sales. Unless revenue recovery is sustained, the company may struggle to support its technology investment, commercial development, and path toward profitability.
Ongoing Negative Free Cash FlowRepeatedly negative operating and free cash flow indicate that the company is consuming cash rather than funding operations internally. Continued burn can deplete reserves over time and increase reliance on external funding, constraining strategic flexibility even with zero reported debt.
Opyl Ltd. News
PKY FAQ
What was Opyl Ltd.’s price range in the past 12 months?
Opyl Ltd. lowest share price was AU$0.01 and its highest was AU$0.07 in the past 12 months.
What is Opyl Ltd.’s market cap?
Opyl Ltd.’s market cap is AU$41.90M.
When is Opyl Ltd.’s upcoming earnings report date?
Opyl Ltd.’s upcoming earnings report date is Mar 04, 2027 which is in 162 days.
How were Opyl Ltd.’s earnings last quarter?
Opyl Ltd. released its earnings results on Aug 31, 2026. The company reported -AU$0.006 earnings per share for the quarter.
Is Opyl Ltd. overvalued?
According to Wall Street analysts Opyl Ltd.’s price is currently Overvalued.
Does Opyl Ltd. pay dividends?
Opyl Ltd. does not currently pay dividends.
What is Opyl Ltd.’s EPS estimate?
Opyl Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Opyl Ltd. have?
Opyl Ltd. has 1,351,573,000 shares outstanding.
What happened to Opyl Ltd.’s price movement after its last earnings report?
Opyl Ltd. reported an EPS of -AU$0.006 in its last earnings report. Following the earnings report the stock price went down -8.889%.
Which hedge fund is a major shareholder of Opyl Ltd.?
Currently, no hedge funds are holding shares in AU:PKY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Opyl Ltd. Stock Smart Score
Company Description
Opyl Ltd.
Pathkey.AI Ltd is an Australian digital health firm that harnesses artificial intelligence (AI) to advance clinical trials and improve the predictability of patient outcomes, particularly within Australia. The company presents a suite of AI-driven solutions: TrialKey, a sophisticated platform for simulating and optimizing trial designs to boost success rates, and TrialGen, an AI-powered utility crafted to simplify the clinical trial design process. They extend their services to a diverse clientele, encompassing biopharmaceutical companies, MedTech innovators, governmental agencies, and various healthcare organizations. Established in Sydney in 1994, the entity known today as Pathkey.AI Ltd will formally change its name from Opyl Limited in August 2025.
Technical Analysis
Cogstate Ltd
―
Oneview Healthcare Chess Depository Interests repr 1
―
Beamtree Holdings Ltd
―
MedAdvisor Limited
―
Alcidion Group Limited
―